Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis. |
| |
| Authors: | Aurelie Fontana Pierre D Delmas |
| |
| Affiliation: | 1. Division of Breast Surgery, Department of Surgery, Brigham and Women''s Hospital, Boston, MA, USA;2. Breast Oncology Program, Dana-Farber/Brigham and Women''s Cancer Center, Boston, MA, USA;3. Department of Pathology, Brigham and Women''s Hospital and Harvard Medical School, Boston, MA, USA;1. Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;2. Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;3. Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;1. Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal, Madrid, España;2. Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, España;3. Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, España;4. Departamento de Medicina, Universidad de Alcalá, Alcalá de Henares, Madrid, España;1. Department of Sensor and Biomedical Technology, School of Electronics Engineering, Vellore Institute of Technology, Vellore 632014, India;2. Department of Physics, School of Advanced sciences, Vellore Institute of Technology, Vellore 632014, India |
| |
| Abstract: | Raloxifene, the first of the second-generation of SERMs to be widely available, represents a significant improvement over tamoxifen. It prevents postmenopausal bone loss and reduces the incidence of vertebral fractures and of new breast cancer cases in osteoporotic patients without stimulating the endometrium. The suggestion that raloxifene could have a beneficial effect on cardiovascular disease in high-risk patients needs to be confirmed in prospective study. Selective estrogen receptors modulators represent a new and promising class of agents for the management of postmenopausal women with a scope that goes far beyond the prevention and treatment of osteoporosis. The observations that estrogens may play a role in bone metabolism of men and that SERMs prevent bone loss and induce a decrease in total serum cholesterol without affecting the prostate in orchidectomized male rats raises the possibility that they also may be of interest for the treatment of elderly men. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
